403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Knight Therapeutics Inc.
(MENAFN- Baystreet) 11:30 AM EST - Knight Therapeutics Inc.: Announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight Therapeutics Inc.
shares T are trading up $0.12 at $10.48.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment